Nob Hill Therapeutics
Overview
Nob Hill Therapeutics is a pioneering biotechnology company based in Albuquerque, New Mexico, focused on developing advanced drug delivery systems. Established in 2016, the company was built on technology licensed from the University of New Mexico's tech transfer arm. Nob Hill has notably raised a total of approximately $3.67 million in funding over several rounds, with key investments from entities such as Tramway Venture Partners and VIC Technology Venture Development. The company is best known for its flagship product, the "DryNeb," a dry powder nebulizer designed to offer efficient pharmacological delivery to the lungs.
Recent Developments
- August 2024: Nob Hill Therapeutics secured a $3 million Series A funding round led by Tramway Venture Partners, also involving TCA Venture Group and VIC Technology Venture Development. This funding aims to advance their breakthrough DryNeb platform and initiate pre-IND studies.
- October 2023: The company received a grant from the U.S. Department of Health and Human Services amounting to $2 million for developing an inhaled therapy targeted at treating lung cancer. This marks a significant milestone in the company’s quest to enter clinical trials.
- May 2023: Nob Hill was featured at the ATS 2023 Respiratory Innovation Summit, where it showcased its advancements in inhalation drug delivery technology.
- September 2022: Noel Greenberger was appointed as the new CEO, marking a strategic pivot towards further technological advancements and market readiness.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2016 |
| Headquarters | Albuquerque, New Mexico |
| Founders | VIC Technology Venture Development |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Tramway Venture Partners, VIC Technology Venture Development, TCA Venture Group |
| Industry | Biotechnology, Drug Delivery |
| Number of Employees | 4 |
Early History
Nob Hill Therapeutics was founded to leverage advanced pulmonary drug delivery systems emerging from innovative research at the University of New Mexico. Initially founded by VIC Technology Venture Development in 2016, the company sought to address significant gaps in the effective delivery of respiratory medications. Early funding rounds focused on validating their DryNeb technology, capable of more efficient delivery of drugs to the lungs than existing inhalers. These efforts culminated in gathering substantial interest from venture capitalists, leading to minor pivots in the company's operational focus as it moved towards clinical trials.
Company Profile and Achievements
Nob Hill Therapeutics focuses its efforts on their DryNeb technology, a notable advancement in the realm of drug delivery devices. DryNeb stands out due to its capability to deliver a wide array of medications directly to a patient's lower respiratory tract, which has applications in treating illnesses such as cystic fibrosis and pulmonary fibrosis.
- 2016: Foundation and early-stage funding saw the company develop its core technology licensed from the University of New Mexico.
- 2018-2020: The company pivoted towards device optimization and early testing, securing further rounds of funding.
- 2022: Transition in leadership to Noel Greenberger, with a focus on accelerating product development.
- 2024: The successful close of a Series A funding round significantly increased the company's operational capacity.
The company's strategic path forward involves partnerships with leading pharmaceutical companies, with a goal to incorporate their technology into broader therapeutic regimens. Their technology platform looks to transform how large dosages of medication can be delivered effectively to the lungs, opening new possibilities in treating pulmonary diseases.
Current Operations and Market Position
Nob Hill Therapeutics operates primarily within the biotechnology sector, focusing on novel drug delivery mechanisms that aim to revolutionize treatments for respiratory diseases. Its DryNeb platform provides a critical competitive advantage in the market, offering a scalable solution to deliver medications directly to the lung tissues, surpassing traditional inhalers. This has positioned Nob Hill favorably among its competitors.
The company is actively engaged in negotiations with pharmaceutical firms to form partnerships that will bolster the clinical testing of its devices. The anticipation of entering clinical trials by the end of 2025 marks a pivotal point in its operational timeline.
Conclusion
Nob Hill Therapeutics exemplifies a focused and innovative approach within the biotechnology landscape, particularly in advancing respiratory healthcare through its patented drug delivery systems. As the company edges closer to clinical trials, its DryNeb technology has the potential to redefine treatment protocols for various lung-related diseases. Looking forward, with strategic partnerships and continued technological evolution, Nob Hill is poised to significantly impact both the drug delivery market and patient care within respiratory medicine.